MK-0524A + Atorvastatin + Simvastatin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mixed Hyperlipidemia
Conditions
Mixed Hyperlipidemia
Trial Timeline
Jan 24, 2006 → Aug 6, 2010
NCT ID
NCT00289900About MK-0524A + Atorvastatin + Simvastatin
MK-0524A + Atorvastatin + Simvastatin is a phase 3 stage product being developed by Merck for Mixed Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00289900. Target conditions include Mixed Hyperlipidemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00289900 | Phase 3 | Completed |
Competing Products
20 competing products in Mixed Hyperlipidemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bempedoic acid 180 mg tablet | Daiichi Sankyo | Approved | 85 |
| olanzapine + lithium + valproate + carbamazepine | Eli Lilly | Phase 3 | 77 |
| Lurasidone + Placebo | Sumitomo Pharma | Phase 3 | 77 |
| Inclisiran + Matching Placebo for Inclisiran | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Approved | 85 |
| Fluvastatin | Novartis | Phase 3 | 77 |
| Atorvastatin + Evolocumab | Amgen | Phase 3 | 76 |
| Evolocumab + Atorvastatin + Placebo to Evolocumab + Placebo to Atorvastatin | Amgen | Phase 3 | 76 |
| Blinatumomab in combination with donor lymphocyte infusion | Amgen | Phase 2 | 51 |
| Evolocumab + Atorvastatin | Amgen | Phase 3 | 76 |
| Evolocumab + Standard of Care | Amgen | Phase 3 | 76 |
| torcetrapib/atorvastatin + atorvastatin | Pfizer | Phase 3 | 76 |
| Bococizumab + Placebo | Pfizer | Phase 3 | 76 |
| tafamidis | Pfizer | Pre-clinical | 22 |
| IBI306 + placebo + placebo + IBI306 | Innovent Biologics | Phase 3 | 76 |
| KarXT | Bristol Myers Squibb | Phase 3 | 76 |
| KarXT | Bristol Myers Squibb | Phase 3 | 76 |
| Gemcitabine + Oxaliplatin | Sanofi | Phase 2 | 51 |
| XL765 (SAR245409) + Temozolomide | Sanofi | Phase 1 | 32 |
| SAL003 140 mg + Placebo | Shenzhen Salubris Pharmaceuticals | Phase 3 | 76 |